title: Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.
abstract: Hepatocellular carcinoma (HCC) is a major pathological type of primary liver cancer. Sorafenib has demonstrated definite efficacy in targeted therapy for HCC. However, when treatment with sorafenib fails, suitable drugs must be found for further treatment. This article reports a case of an HCC patient who was treated with angiogenesis inhibitor axitinib and c-Met inhibitor cabozantinib following treatment with sorafenib. The report focuses on clinical treatment and toxicity. Rational application of targeted therapy is also explored.
authors: a Department of Oncology ; The First Affiliated Hospital of Dalian Medical University ; Dalian , PR China.
authors: Bin
authors: B
authors: Zhang
authors: Xia
authors: X
authors: Zhang
authors: Tao
authors: T
authors: Zhou
authors: Jiwei
authors: J
authors: Liu
mesh_terms: D000813:Anilides / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077784:Axitinib; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000188:drug therapy*; D017809:Fatal Outcome; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007191:Indazoles / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage; D019233:Retreatment; D000077157:Sorafenib; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000813:Anilides; D007093:Imidazoles; D007191:Indazoles; D010671:Phenylurea Compounds; D011725:Pyridines; C558660:cabozantinib; D009536:Niacinamide; D000077157:Sorafenib; D000077784:Axitinib
keywords: Alpha-fetoprotein; Axitinib; Cabozantinib; Hepatocellular carcinoma; Primary liver cancer; Sorafenib; c-Met